ROTARY CLUB OF MANILA JOURNALISM AWARDS
2006 National Newspaper of the Year 2011 National Newspaper of the Year 2013 Business Newspaper of the Year 2017 Business Newspaper of the Year 2019 Business Newspaper of the Year
BusinessMirror
www.businessmirror.com.ph
A broader look at today’s business n
Sunday, May 3, 2020 Vol. 15 No. 206
EJAP JOURNALISM AWARDS
BUSINESS NEWS SOURCE OF THE YEAR (2017, 2018)
DEPARTMENT OF SCIENCE AND TECHNOLOGY
2018 BANTOG MEDIA AWARDS
PHILIPPINE STATISTICS AUTHORITY
DATA CHAMPION
P25.00 nationwide | 2 sections 12 pages | 7 DAYS A WEEK
BIRDS peck at food near the Forbidden City, usually crowded with tourists before the new coronavirus outbreak in Beijing, April 19, 2020. AP/ANDY WONG
Ending where it all began? As several pharma giants in countries across the globe race for a vaccine to end the pandemic nightmare, some Chinese experts deem ‘inactive’ Covid-19 virus as best way to lick the disease.
C
By Rene Acosta
HINA is currently developing six vaccines in the global race to stop the novel coronavirus 2019 (Covid-19), and three of the candidate medicines are already in the second stage of human clinical trials. Beijing’s lead in the development of an antidote to the deadly pathogen across the globe should not come as a surprise, given that the strain was first detected in one
of its cities in December before it spun and mutated into an international health crisis. A Filipino journalist working in China said that the country is
accelerating its development of the six vaccines, three of which—one adenovirus vector type and two inactive type—are already in Stage 2 of human clinical testing, giving hope that the disease blamed for the deaths of more than 200,000 around the world may soon be stopped in its tracks. “As of April 29, 2020, China already has three vaccines that are on phase two of human clinical trials,” said Rhio Zablan, who had been in Beijing for the last 10 years and currently works for Filipino Service of the China Media Group (SF-CMG), which he describes as a national-level media organization in China.
Pack leader
“CHINA is the first country to have gone through phase two of human clinical trials in vaccine development,” said Zablan, who had worked for the Philippine government’s News and Information Bureau under the Office of the Press Secretary in Manila before joining the Chinese media. Zablan’s claim of China pulling out all the stops against Covid-19 appeared to corroborate the recent brouhaha involving Armed Forces Chief of Staff Gen. Felimon Santos Jr., whose leaked letter to the Chinese ambassador in Manila showed he had sought the intercession of the diplomat for him to
procure Carrimycin tablets for his friends afflicted by the virus. Santos, who recovered from the disease, apparently took the medicine, a Chinese governmentregulated drug and only available in China, thus prompting him to secure it for his unidentified friends. He claimed the letter was personal although it bears the letterhead of his office. Santos withdrew his request on learning that the medicine had not been approved for use in the Philippines by the Food and Drug Administration (FDA). According to Zablan, the Chinese government has named the adenovirus vector vaccine as Ad5nCoV.
“The adenovirus vector vaccine, just like the Ad5-nCoV, uses chemically weakened virus so that it can send pathogen into the human body. This is a new type of vaccine that can be mass-produced, safe and can generate strong immune response,” he said. The Ad5-nCoV was jointly developed by the CanSino Biologics Inc. and the Institute of Biotechnology of China’s Academy of Military Medical Sciences. On the other hand, Zablan said the two inactive vaccines have not been named yet. They were manufactured by the Wuhan Institute of Biological Products Co. and Wuhan Continued on A2
Road from lockdown to liberty is paved with economic trade-offs
T
By Enda Curran & Claire Che Bloomberg News
HE world economy is entering a new stage of the coronavirus crisis as governments inch toward easing restrictions.
It’s a phase that entails stark trade-offs between economic growth and risking another wave of infections and death. Some countries, like China and South Korea, are firing up their economic engines already, having contained the virus—for now at least. Others, including hard-hit Italy and the US, are preparing to reopen their wounded economies, even as they still fight to get a lid on infections. It’s clear that the longer the lockdowns endure, the steeper the economic blow. But China’s experience demonstrates reopening won’t happen overnight—March data showed production was recov-
ering but consumers remain wary. Meantime, Singapore presents a cautionary tale for those reopening—it’s seen a second wave that’s prompted stricter and extended restrictions, with an accompanying deeper blow to the island economy anticipated.
First movers
IN China, the lifting on April 8 of the unprecedented lockdown on Wuhan—where the virus pathogen first emerged—was a milestone. Stringent nationwide restrictions meant the world’s second-largest economy recorded its deepest contraction in decades over the first quarter.
PESO EXCHANGE RATES n US 50.5890
Even now, companies and workers in the central Chinese city continue to undergo daily temperature checks and disinfection of facilities. Malls have reopened but with much fewer shoppers than the pre-virus days and suspicions remain about the true scale of the epidemic. The faster-thananticipated resumption prompted Bloomberg Economics to increase its gross domestic product (GDP) growth forecasts for China to an expansion this year of 2 percent, up from 1.4 percent in its previous forecast, yet far below the actual growth rate of 6.1 percent in 2019. South Korea curbed the virus without a full-fledged lockdown due to its aggressive testing and tracing efforts, which pioneered drive-in centers and phone stalls for testing. That approach has softened the economic hit even as external demand has slumped. Bloomberg Economics projects Korea’s economy will contract 0.1 percent year on year in 2020 in their base case, and bounce back with a 3.3-percent expansion in 2021. Continued on A2
n JAPAN 0.4744 n UK 63.1047 n HK 6.5274 n CHINA 7.1489 n SINGAPORE 35.8381 n AUSTRALIA 33.1661 n EU 55.0155 n SAUDI ARABIA 13.4610
Source: BSP (April 30, 2020)